Specialty Pharma Journal Specialty, Precision & Technology
NORTH CHICAGO, Ill., March 4, 2016 /PRNewswire/ — AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) approved IMBRUVICA® (ibrutinib) as a first-line treatment for patients with chronic lymphocytic leukemia (CLL).1 The approval is based on data from the randomized, multi-center, open-label Phase 3 …
Tag Archives: ibrutinib
March, 2016
May, 2015
-
27 May
AbbVie Completes $21 Billion Acquisition of Pharmacyclics
AbbVie has completed its $21 billion acquisition of Pharmacyclics, Inc., strengthening its oncology portfolio. The company said that it has completed the acquisition of Pharmacyclics, a leader in the hematological oncology market with its blockbuster drug Imbruvica (ibrutinib). Imbruvica is a first-in-class BTK-inhibitor used to treat hematological cancers, a $24 …
April, 2015
-
10 April
New Drug for Rare Lymphoma Demonstrates Sustained Benefit at Two Years
New data shows that Pharmacyclics and partner Janssen’s Imbruvica (ibrutinib) provides ongoing control of Waldenstrom’s macroglobulinemia (WM). Investigators from Dana-Farber Cancer Institute reported that the most recent results from a clinical trial show that ibrutinib continued to control the rare blood cancer, with 95 percent of patients surviving for two …
March, 2015
-
16 March
Imbruvica Demonstrates Promising Results in Phase III Trial in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Janssen Biotech, Inc. and partner Pharmacyclics, Inc. announced that an Independent Data Monitoring Committee determined that its late-stage trial, evaluating Imbruvica in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) met its primary endpoint. According to the companies, during a pre-planned interim analysis of the Phase III …